Browse TCL1A

Summary
SymbolTCL1A
NameT-cell leukemia/lymphoma 1A
Aliases TCL1; T-cell lymphoma-1; oncogene TCL-1; oncogene TCL1; protein p14 TCL1; T-cell leukemia/lymphoma protein 1 ......
Chromosomal Location14q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus Microsome Endoplasmic reticulum Note=Microsomal fraction.
Domain PF01840 TCL1/MTCP1 family
Function

Enhances the phosphorylation and activation of AKT1, AKT2 and AKT3. Promotes nuclear translocation of AKT1. Enhances cell proliferation, stabilizes mitochondrial membrane potential and promotes cell survival.

> Gene Ontology
 
Biological Process -
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04151 PI3K-Akt signaling pathway
Reactome -
Summary
SymbolTCL1A
NameT-cell leukemia/lymphoma 1A
Aliases TCL1; T-cell lymphoma-1; oncogene TCL-1; oncogene TCL1; protein p14 TCL1; T-cell leukemia/lymphoma protein 1 ......
Chromosomal Location14q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TCL1A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TCL1A and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
19332800Chronic lymphocytic leukemiaInhibit immunityWith development of leukemia, Emu-TCL1 transgenic mice developed functional T-cell defects and alteration of gene and protein expression closely resembling changes seen in CLL human patients. Furthermore, infusion of CLL cells into young Emu-TCL1 mice induced defects
Summary
SymbolTCL1A
NameT-cell leukemia/lymphoma 1A
Aliases TCL1; T-cell lymphoma-1; oncogene TCL-1; oncogene TCL1; protein p14 TCL1; T-cell leukemia/lymphoma protein 1 ......
Chromosomal Location14q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TCL1A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTCL1A
NameT-cell leukemia/lymphoma 1A
Aliases TCL1; T-cell lymphoma-1; oncogene TCL-1; oncogene TCL1; protein p14 TCL1; T-cell leukemia/lymphoma protein 1 ......
Chromosomal Location14q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TCL1A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.6980.273
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.1670.254
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.350.693
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4880.43
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4290.668
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5580.631
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.4990.109
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.5670.253
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.480.312
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1740.129
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2650.795
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1980.537
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TCL1A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolTCL1A
NameT-cell leukemia/lymphoma 1A
Aliases TCL1; T-cell lymphoma-1; oncogene TCL-1; oncogene TCL1; protein p14 TCL1; T-cell leukemia/lymphoma protein 1 ......
Chromosomal Location14q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TCL1A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTCL1A
NameT-cell leukemia/lymphoma 1A
Aliases TCL1; T-cell lymphoma-1; oncogene TCL-1; oncogene TCL1; protein p14 TCL1; T-cell leukemia/lymphoma protein 1 ......
Chromosomal Location14q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TCL1A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TCL1A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTCL1A
NameT-cell leukemia/lymphoma 1A
Aliases TCL1; T-cell lymphoma-1; oncogene TCL-1; oncogene TCL1; protein p14 TCL1; T-cell leukemia/lymphoma protein 1 ......
Chromosomal Location14q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TCL1A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTCL1A
NameT-cell leukemia/lymphoma 1A
Aliases TCL1; T-cell lymphoma-1; oncogene TCL-1; oncogene TCL1; protein p14 TCL1; T-cell leukemia/lymphoma protein 1 ......
Chromosomal Location14q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TCL1A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTCL1A
NameT-cell leukemia/lymphoma 1A
Aliases TCL1; T-cell lymphoma-1; oncogene TCL-1; oncogene TCL1; protein p14 TCL1; T-cell leukemia/lymphoma protein 1 ......
Chromosomal Location14q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TCL1A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTCL1A
NameT-cell leukemia/lymphoma 1A
Aliases TCL1; T-cell lymphoma-1; oncogene TCL-1; oncogene TCL1; protein p14 TCL1; T-cell leukemia/lymphoma protein 1 ......
Chromosomal Location14q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TCL1A collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.